Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

143.72 -1.09 (-0.75%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
78 79 Next >
News headline image
Gilead Leads The Battle Vs. HIV. But Rivals Are On The Move. ↗
Gilead stock is closely tied to its HIV treatments. But with Biktarvy's patent expirations looming, can the giant survive? 
Via Investor's Business Daily
Topics Intellectual Property
News headline image
Kalshi Will Let Traders Bet on FDA Drug Approvals Despite Critics' Insider Trading Warnings ↗
Kalshi is expanding into biotech with contracts on FDA drug approvals from Sanofi and Gilead, as critics warn the wagers invite insider trading. 
Via Benzinga
News headline image
Invesco Healthcare ETF vs VanEck Biotech: Which ETF Will Deliver the Healthiest Returns for 2026? ↗
RSPH offers 60 diversified holdings with lower volatility, while BBH concentrates on 25 biotech leaders with stronger recent returns. 
Via The Motley Fool
Topics ETFs
News headline image
Spotting Winners: Gilead Sciences (NASDAQ:GILD) And Therapeutics Stocks In Q1
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ... 
Via StockStory
Topics Artificial Intelligence
Gilead Sciences Inc (NASDAQ:GILD): A Sustainable Dividend Leader in the Biotechnology Sector ↗
Via Chartmill
News headline image
Many Investors Are Still Treating Gilead Sciences Like a Has-Been HIV Stock. 4 Drug Launches This Year Could Prove Them Wrong. ↗
Gilead's expansion beyond HIV therapies will surprise many investors. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Which is Best for Investors: Healthcare Stability (XLV) or Biotech Growth (IBBQ)? ↗
IBBQ surged 54.5% in one year but carries deeper drawdowns. XLV offers broader diversification, lower costs, and double dividend yield for steadier returns. 
Via The Motley Fool
Topics ETFs
News headline image
Which is the Better Choice for Healthcare Investors? IYH or BBH? ↗
BBH delivered 33.6% returns but swung 39.9% lower; IYH's 100 holdings offer steadier performance with 1.2% dividend yield. 
Via The Motley Fool
Topics ETFs
What's going on in today's session: S&P500 movers ↗
Via Chartmill
News headline image
2 Recession-Resistant Dividend Stocks to Buy and Hold ↗
You don't need to predict a recession to prepare your portfolio. These two stocks can help. 
Via The Motley Fool
Topics Economy
News headline image
IHE vs. IBB: Which iShares Healthcare ETF Is the Better Buy? ↗
Established pharmaceutical giants have delivered lower volatility and higher income than clinical-stage biotech exposure over the past five years. 
Via The Motley Fool
Topics ETFs
News headline image
Which Healthcare ETF Is the Better Buy: Invesco's IBBQ or State Street's XPH? ↗
IBBQ offers lower costs and broader diversification, while XPH delivered stronger 1-year returns with less volatility. 
Via The Motley Fool
Topics ETFs
News headline image
BBH vs. XPH: Which Healthcare ETF Is Better for Beginners? ↗
Broader diversification and lower volatility set these healthcare ETFs apart, with each fund targeting a distinct segment of the industry. 
Via The Motley Fool
Topics ETFs
Stay informed with the top movers within the S&P500 index on Tuesday. ↗
Via Chartmill
News headline image
Generic Fears Overdone? Gilead Stock Has More Room to Run, Analyst Says ↗
HSBC upgrades Gilead Sciences (GILD) to Buy, raising its price target to $155 on strong long-acting HIV & oncology potential. 
Via Benzinga
MissionIRNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Shareholders Should Watch Novartis Latest $1.5 Billion ADC Acquisition
Via Investor Brand Network
News headline image
FHLC vs. BBH: Which Healthcare ETF Is the Better Buy? ↗
Compare fees, diversification, and risk between these two leading healthcare ETFs. 
Via The Motley Fool
Topics ETFs
News headline image
If You Invested $1000 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today ↗
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 2.07% on an annualized basis producing an average annual return of 11.3%. Currently, Gilead Sciences has a market... 
Via Benzinga
News headline image
SPDR Health Care ETF Tops iShares Biotech in Long-Term Returns ↗
Compare portfolio diversity, risk profiles, and income potential as you weigh these two leading healthcare ETFs. 
Via The Motley Fool
Topics ETFs
News headline image
Gilead's Trodelvy Expands Reach With New FDA Approval In Breast Cancer ↗
FDA approves Gilead's Trodelvy for first-line metastatic triple-negative breast cancer, expanding use alone and with Keytruda. 
Via Benzinga
News headline image
This ETF Has More Than Doubled the S&P 500's Returns Over the Past Decade. Is It a Buy for the Next Decade? ↗
It may not duplicate those impressive results, but it has all the tools it needs. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Stocks
News headline image
U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
Via Investor Brand Network
BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Targets Next Generation of DNA Damage Response Cancer Therapies
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch. ↗
The iShares Nasdaq Biotechnology ETF (IBB) is trading just 1.47% below its 52-week high, signaling a potential multi-year sector breakout. 
Via MarketBeat
Topics ETFs
News headline image
European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
From BioMedWire
Via GlobeNewswire
News headline image
3 S&P 500 Stocks with Exciting Potential
The S&P 500 (^GSPC) is packed with companies that have built dominant market positions, making it a core index for investors. A select few continue to innova... 
Via StockStory
Topics Stocks
News headline image
Gilead Sciences (GILD): Buy, Sell, or Hold Post Q1 Earnings?
Since December 2025, Gilead Sciences has been in a holding pattern, posting a small return of 2.7% while floating around $124.73. The stock also fell short o... 
Via StockStory
News headline image
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
78 79 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.